Jubilant Life Sciences shares hit new record high of Rs 546.70 on Thursday after the company announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension. At 1.07 pm, shares of the global pharmaceuticals and life sciences company were trading 5.97 per cent up at Rs 537.30. The scrip opened the day at Rs 510.10 and has touched a high and low of Rs 546.70 and Rs 510.10, respectively, in trade so far. Later, the scrip ended 4.63 per cent up at Rs 530.55.
In a BSE filing, the company said, “As on June 30, 2016, the company had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.”
Promoters hold 54.02 per cent stake in the company, while public and others hold 43.53 per cent and 2.44 pe rcent stake in the company, according to the data available with BSE.
For the quarter ended June 30, 2016, the company reported a consolidated net profit of Rs 161.60 crore, up 22.49 per cent, against Rs 131.93 crore in the corresponding quarter a year ago. Net sales of the company fell 1.72 per cent year-on-year to Rs 1,400.97 crore during the quarter under review from Rs 1425.53 crore in the same quarter last fiscal. Operating profit of the company grew by 13.25 per cent year-on-year to Rs 372.45 crore for the quarter ended June 30, 2016.